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INTRODUCTION 
High-dose therapy with hematopoietic stem cell (HSC)
transplantation has become recognized as an effective ther-
apy in patients with relapsed non-Hodgkin’s lymphoma
(NHL) [1-3]. Approximately 40% of those patients whose
disease is still responsive to therapy have long-term disease-
free survival after high-dose therapy and autologous HSC
transplantation. A randomized prospective trial showed that
the combination of high-dose therapy and autologous bone
marrow transplantation (BMT) is superior to conventional-
dose salvage chemotherapy in treating patients with relapsed
diffuse aggressive lymphoma [1]. Studies in patients with
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ABSTRACT
Contamination of hematopoietic stem cells (HSCs) with tumor cells has been associated with increased incidence of
relapse in patients with non-Hodgkin’s lymphoma following autologous HSC transplantation. Effective purging of
tumor cells may improve the results of HSC transplantation, but current methods of purging are technically difficult
to perform with large numbers of cells and do not consistently remove all detectable cells. We report a pilot clinical
trial in which 10 patients with relapsed B-cell non-Hodgkin’s lymphoma received high-dose chemotherapy followed
by infusion of autologous HSCs depleted of B-cells by high-density microparticles (HDM) coated with anti-CD19
and anti-CD20 monoclonal antibodies (BCell-HDM). HSCs were mobilized with cyclophosphamide and granulocyte
colony-stimulating factor. In 6 of the 10 patients, B-cells were detectable by immunocytochemical analysis of the
apheresis products prior to treatment. Following treatment with the BCell-HDM, no B-cells were detected in the
products from 5 of these patients, a result representing a median depletion of >2.2 logs (range, >0.4 to >5.1 logs).
The median recovery of nontarget cells postdepletion was 73% for CD34+ cells and 78% for CD3+ cells. All patients
received high-dose cyclophosphamide, BCNU (carmustine), and etoposide prior to reinfusion of their B-cell–
depleted autologous HSCs. The median number of CD34+ cells cryopreserved was 3.6 × 106 cells/kg (range,
2.2-10.1 × 106 cells/kg). Engraftment was rapid in all cases, with a median time to achieve an absolute neutrophil
count of 0.5 × 109/L of 10 days (range, 8-11 days). The median time to achieve a platelet count of 20 × 109/L unsup-
ported by platelet transfusion was 11.5 days (range, 8-17 days). This nonmagnetic negative-depletion technology is
simple, rapid, and effective in depleting target cells to undetectable levels, with excellent recovery of nontarget cells.
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indolent lymphomas also suggest that a subset of patients
experience long-term disease-free survival following high-
dose therapy with autologous stem cell support [4-11].
An important consideration in autologous HSC trans-
plantation is the potential for contamination of the stem cell
product by reinfusion of tumor cells. Studies involving
genetic marking of autologous marrow prior to infusion sug-
gest that contaminating tumor cells contribute to relapse in
patients with neuroblastoma, acute myeloid leukemia, and
chronic myeloid leukemia [12,13]. Additional evidence has
come from studies employing high-dose chemoradiotherapy
followed by reinfusion of anti–B-cell monoclonal antibody–
purged autologous bone marrow in patients with B-cell NHL
[5,6,14]. The detection of lymphoma cells by polymerase
chain reaction (PCR) in the treated bone marrow following
ex vivo bone marrow purging was a highly signiﬁcant predic-
tor of subsequent relapse. Conversely, the absence of residual
lymphoma cells detectable by PCR in the reinfused marrow
was strongly associated with continuing complete remission.
Additional indirect evidence that residual tumor cells con-
tribute to relapse has been shown in aggressive lymphomas,
in which the ability to culture malignant cells from the har-
vested stem cell product was highly predictive of subsequent
relapse following high-dose therapy [15]. Current technol-
ogy for purging autologous stem cell products of lymphoma
cells has limitations. Techniques that select CD34+ pro-
genitor cells have been shown to reduce the number of
tumor cells in the autograft by approximately 3 logs [16,17].
However, an increased incidence of infection posttransplan-
tation has been described, presumably due to the removal of
normal immune effector cells from the graft [18,19]. A com-
bination of multiple monoclonal antibodies and rabbit com-
plement can deplete approximately 2 to 4 logs of tumor cells,
albeit with some variability [20]. However, this technology
is time-consuming and relies on nonstandardized biological
reagents. It is also difﬁcult to apply to peripheral blood samples
because of the high cell numbers harvested compared to bone
marrow samples. Immunomagnetic beads with anti–B-cell
monclonal antibodies have also been used to deplete neoplas-
tic cells from stem cell collections [21,22]. More recently, in
vivo purging of B-cells with rituximab administered prior to
stem cell mobilization and apheresis has been reported
[23,24]. Here we report the use of a new negative-depletion
technology that uses high-density microparticles (HDM)
made of nickel and coated with anti–B-cell monoclonal anti-
bodies (BCell-HDM) to deplete B-cells from autologous
peripheral blood stem cell (PBSC) preparations prior to
transplantation in patients with relapsed B-cell NHL [25-28].
The objectives of the pilot study were to evaluate the extent
of B-cell depletion and recovery of CD34+ cells and CD3+
T-cells in the treated autologous PBSCs, to evaluate engraft-
ment following infusion of the HDM-treated PBSCs, and to
evaluate infusional toxicity of the HDM-treated PBSCs.
Treatment of PBSC collections with the BCell-HDM was
associated with high recovery of CD34+ cells and T-cells and
>2 logs of depletion of B-cells. Moreover, reinfusion of the
treated cells was safe, and engraftment was prompt. This
rapid and effective approach for depleting malignant B-cells
will permit the undertaking of further clinical trials to evalu-
ate the role of ex vivo purging of tumor cells prior to autolo-
gous transplantation.
MATERIALS AND METHODS
Selection of Patients and Treatment Protocol 
Patients were eligible for this study if they were younger
than 65 years, had B-cell NHL as deﬁned in the National
Cancer Institute Working Formulation or Revised European-
American Lymphoma (REAL) classification, and had
relapsed after standard chemotherapeutic regimens [29,30].
Lymphoma cells of eligible patients had to demonstrate
CD20 and/or CD19 expression conﬁrmed by results of ﬂow
cytometric or immunhistochemical analysis as described [31].
Patients had to have sensitive disease and achieve minimal
disease status deﬁned as lymph node masses less than 5 cm in
greatest diameter and histologic evidence of bone marrow
involvement of 20% or less of the intratrabecular space as
determined by iliac crest biopsy. Additional criteria for entry
included the absence of comorbid disease of the heart, kid-
ney, lung, and liver and a Karnofsky score above 80%.
Informed consent was obtained from all patients. High-dose
chemotherapy consisted of the CBV regimen of cyclophos-
phamide, BCNU (carmustine), and VP-16 (etoposide). The
dosages were as follows: cyclophosphamide 750 mg/m2 twice
daily intravenously (IV) on days –6, –5, –4, and –3; BCNU
112.5 mg/m2 once daily IV on days –6, –5, –4, and –3; and
VP-16 200 mg/m2 twice daily IV on days –6, –5, –4, and –3,
as described [32]. The cryopreserved PBSCs were thawed
and infused rapidly through a central venous catheter on day
0. Posttransplantation granulocyte colony-stimulating factor
(G-CSF) was given at a dosage of 5 µg/kg per day subcuta-
neously beginning on day +1, until the absolute neutrophil
count (ANC) exceeded 1.0 × 109/L. Supportive care was pro-
vided as previously described [5].
PBSC Mobilization and Collection
PBSCs were mobilized using cyclophosphamide, 3 g/m2
infused IV over 2 hours, followed 1 day later by G-CSF,
10 µg/kg subcutaneously daily until completion of apheresis.
Leukapheresis components were collected when the ANC
was >1.0 × 109/L. Three total blood volumes were processed
each day (for a maximum of 4 days) until a minimum of 2 ×
106 CD34+ cells/kg had been isolated after processing with
the BCell-HDM Cell Separation System. For the first
2 patients enrolled, an additional apheresis component con-
taining at least 1 × 106 CD34+ cells/kg was collected and
cryopreserved without purging for use in the event of
delayed engraftment or nonengraftment of the BCell
HDM-treated PBSC.
Treatment of PBSC with BCell-HDM
BCell-HDM consists of vials of high-density micro-
particles (HDM) covalently bound to murine monoclonal
antibodies recognizing CD19 (CD19-HDM) and CD20
(CD20-HDM). One vial of CD19-HDM and 1 vial of
CD20-HDM are required for each depletion cycle. BCell-
HDMs are a component of the Eligix Cell Separation System,
currently manufactured by BioTransplant Inc (Charlestown,
MA). A magnet is used in the system to hold the HDM pellet
in place during chamber inversion but is not required for
cell separation.
All procedures were performed using sterile technique
in a class II type A biosafety cabinet according to the manu-
facturer’s instructions. For each procedure, the HDM were
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introduced into 4 sterile disposable 225-mL conical tubes,
hereafter referred to as depletion chambers, and washed
with normal saline. The leukapheresis product was washed
once in normal saline supplemented with autologous plasma
and resuspended in normal saline at a ﬁnal volume of 220 mL.
The washed product was added to the ﬁrst depletion cham-
ber and gently agitated to suspend both the HDM particles
and cells. The cells and HDM were then placed on a rotator
that gently and constantly inverted the depletion chamber in
an end-over-end fashion, permitting the HDM to constantly
settle through the cell suspension and collide with target
cells. After 5 minutes, rotation was stopped and the deple-
tion chamber was left upright on the rotator for an addi-
tional 5 minutes, allowing the HDM particles to settle by
gravity. A magnet was used to retain BCell-HDM and cap-
tured CD19+ and CD20+ cells, and the cells remaining sus-
pended in the chamber were aseptically transferred to the
next depletion chamber. A total of 4 depletion cycles were
performed for each component. Following the fourth deple-
tion, the depleted stem cell product was transferred to a
sterile ﬁnal particle capture chamber, secured to the HDM
magnet, and placed on the HDM rotator for 5 minutes to
capture any residual HDM not retained in the third cham-
ber used. The cells were then washed 3 times and resus-
pended in autologous plasma. After removal of samples for
the required assays, the B-cell–depleted component was
then cryopreserved using controlled-rate freezing and
stored in vapor-phase liquid nitrogen until required for use.
Analysis of B-Cell Purging Efficiency 
An immunocytochemical assay for detection of rare
events was modified to detect total CD20+ B-cells in the
PBSC products pre– and post–B-cell processing [33].
Brieﬂy, mononuclear cells were isolated by Ficoll-Hypaque
separation (Pharmacia, Upsala, Sweden), washed twice in
Leibovitz L-15 medium (GIBCO/BRL, Grand Island, NY)
supplemented with 10% fetal bovine serum, and resus-
pended to a concentration of 1 × 107 cells/mL; 3 × 106 cells
were placed on slide cytopreparations and immunostained.
Cytopreparations were fixed with paraformaldehyde/
methanol, washed thoroughly in Dulbecco’s phosphate-
buffered saline, and incubated with murine monoclonal
antibody, antihuman CD20 (Beckman Coulter, Hileah, FL).
Alkaline phosphatase immunostaining was performed as
previously described. Slides were evaluated by one reviewer,
and the total number of CD20+ cells per slide was recorded.
The limit of detection of this assay was approximately
1 CD20+ cell per 106 nucleated cells.
Recovery of Nontarget Cells 
CD34+, CD3+, CD4+, and CD8+ cells were measured by
2-color flow cytometry using a Coulter Epics XL flow
cytometer. Samples were removed from the PBSC products
prior to and following depletion. These samples were then
diluted in 1 mL of autologous plasma and stored at 2°C to
8°C until assayed. For the ﬁrst 3 patients, CD34+ cells were
enumerated by determining the percentage of CD45dim cells
that were also CD34+. For the subsequent 7 patients,
absolute counting methodology was used [34]. The remain-
ing pre- and postdepletion samples were stained with
CD3–ﬂuoroscein isothiocyanate (FITC)/CD19-phycoerythrin
(PE), CD3-FITC/CD4-PE, and CD3-FITC/CD8-PE
(Beckman Coulter); prepared using the Q-prep device; ﬁxed
with 1% formalin solution; and analyzed by standard ﬂow
cytometric methods.
Monitoring Levels of Nickel Murine Immunoglobulin
and Human Antimouse Antibody
Serum and urine samples for determination of nickel
concentration were collected prior to PBSC infusion and at
24 hours and 1 week after infusion. Nickel concentration
was measured by atomic absorption (Galbraith Laborato-
ries). The limit of detection of the assay was 14.4 µg/mL.
Enzyme-linked immunosorbent assays were used to test the
pre- and postdepletion apheresis products for the presence
of murine immunoglobulin (Ig) (an IgG1 assay to detect
anti-CD19 and an IgG2a assay to detect anti-CD20). The
limit of detection of the assay was 0.78 ng/mL. Testing for
human antimouse antibody (HAMA) response (Dianon Sys-
tems, Stratford, CT) was performed on patient serum at
screening, at day +100, and 6 and 12 months posttransplan-
tation. The limit of detection of the assay was 74 ng/mL.
RESULTS 
Patient Characteristics
Fifteen patients with recurrent B-cell NHL received
mobilization chemotherapy. PBSC mobilization was ade-
quate in 10 patients, who then received high-dose therapy
followed by infusion of BCell-HDM–modified PBSCs.
The characteristics of these 10 patients prior to autologous
stem cell transplantation (ASCT) are detailed in the Table.
The median age of these patients was 53.5 years (range,
38-64 years). Histological analysis results indicated diffuse
large B-cell lymphoma in 7 patients, follicular lymphoma
grade I/II in 2 patients, and mantle cell lymphoma in
1 patient. Prior to mobilization all patients were in a mini-
mal disease state, with 3 patients having overt histologic
bone marrow involvement. 
Analysis of Ex Vivo Stem Cell Treatment 
Ten patients underwent apheresis and had adequate
PBSC mobilization. Seven of these 10 patients required
only a single apheresis to reach the required CD34+ target
number of 2 × 106/kg; 2 patients required 3 aphereses, and
Patient Characteristics
Total no. of patients 15
Inadequate stem cell collection 5
NHL histology at ASCT (n = 10), no. of patients
Follicular center cell grade I or II 2
Diffuse large B-cell lymphoma* 7
Mantle cell lymphoma 1
Median age at transplantation (range), y 53.5 (38-64)
Bone marrow involvement with NHL at ASCT 3
Prior therapy
Median no. of chemotherapy regimens (range) 3 (1-6)
No. of patients with prior radiation therapy 2
*Includes 2 patients with a history of indolent lymphoma whose dis-
ease transformed to aggressive histology lymphoma.
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1 patient required 4 aphereses. Six patients had B-cells
detectable by immunohistochemical analysis of the prede-
pletion product, 3 patients had no detectable B-cells, and
1 patient was unevaluable because of high background stain-
ing. Following cell processing with the BCell-HDM, no
B-cells were detected in any of the apheresis products from
5 of these 6 initially positive patients. One patient had
detectable B-cells in both pre- and postdepletion products.
The mean log reduction of B-cells was >2.4 logs (median,
>2.2 logs; range, >0.4 to >5.1 logs). The pre- and postdeple-
tion products were examined by ﬂow cytometry for numbers
of CD34+, CD3+, CD4+, and CD8+ cells. The median recov-
eries of CD34+, CD3+, CD4+, and CD8+ cells postdepletion
were 80%, 81%, 74%, and 72%, respectively. These results
were not corrected for losses due to cell sampling.
Because murine antibodies are a component of the
BCell-HDM, we examined postdepletion apheresis products
in all patients for the presence of murine antibodies, and
none were detected in any products from the 10 patients.
Reinfusion of BCell-HDM–Treated Cells and
Engraftment 
Toxicities related to infusion of BCell-HDM–treated
product occurred in 3 patients. The toxicities were mild and
consistent with sequelae associated with infusion of unma-
nipulated products cryopreserved with dimethylsulfoxide.
Grade 1 toxicities included nausea, vomiting, dyspnea,
cough, altered taste, ﬂushing, tachycardia, and hypotension.
One patient had grade 3 hypertension. No nickel levels
above background were detected in any serum or urine sam-
ples in any patient after PBSC reinfusion. No patient had a
detectable nickel allergic response. HAMA levels were
assessed prior to treatment and at 100 days, 6 months, and
12 months following ASCT. No patient had a detectable
HAMA response following PBSC reinfusion. The median
time to achieve an ANC of 500/µL was day +10 (range, day 8
to day 11) and the median time to reach a platelet count of
20,000/µL unsupported by platelet transfusion was day +11.5
(range, day 8 to day 17). Durability of engraftment at day
+30 posttransplantation was demonstrated in all patients.
Treatment Outcome
Of the 10 patients treated, none suffered early treatment-
related deaths. As of March 28, 2001, 5 patients had
relapsed, at 2.5, 8.5, 19.3, 19.5, and 22.6 months. The other
5 patients remained alive and in complete remission with a
median follow-up of 16 months (range, 7 to 20.5 months).
The Kaplan-Meier estimate of patients alive and disease-free
at 16 months is 79% (90% conﬁdence interval, 57%-100%).
Only 1 patient died, at 16 months posttransplantation, fol-
lowing relapse at 2.5 months. Of the 5 patients who
relapsed, 4 relapsed in sites of prior disease and 1 in both
prior and new sites.
DISCUSSION 
A major question regarding the use of autologous or
peripheral blood as sources of stem cells following high-dose
therapy is whether reinfused tumor cells may in fact con-
tribute to relapse in these patients. Upwards of 70% of
patients with follicular NHL have histologic evidence of
bone marrow involvement at diagnosis and virtually all
patients with relapse have bone marrow positive for tumor
cells at the time of relapse [35]. In a study from our institu-
tion, all patients had bone marrow involvement, detectable
by PCR assay for the bcl-2 translocation, at the time of bone
marrow harvest, even if the bone marrow appeared histologi-
cally negative for tumor cells [36]. Similar evidence for the
presence of PCR-detectable occult disease in the presence of
histologically normal marrow has been reported from other
centers [37-41]. In light of the studies suggesting that rein-
fused tumor cells contribute to relapse [12,13], several
approaches have been taken to provide a tumor-free stem
cell preparation. These approaches include immunologic and
pharmacologic techniques to purge malignant cells from the
graft, as well as steps to enrich for normal hematopoietic
progenitors through CD34 selection [4-6,8,10,14,31,42,43].
Although the primary source of stem cells has largely shifted
from bone marrow to peripheral blood, there is no evidence
that peripheral blood is a tumor cell–free source of hemato-
poietic stem cells [44]. Techniques that preserve stem cell
numbers but effectively deplete neoplastic cells may address
the contribution of tumor cell contamination to relapse fol-
lowing high-dose therapy.
One of the problems of current positive and negative
selection techniques is the loss of normal progenitor and
effector cells. This pilot study demonstrated that the BCell-
HDM Cell Separation System used to deplete B-cells from
autologous PBSCs was not associated with any delay in
engraftment of neutrophils or platelets. The median times to
reach an ANC of 500/µL and a platelet count of 20,000/µL
were similar to those expected from infusion of the same
number of CD34+ cells in an unmanipulated autograft [45].
The BCell-HDM cell separation device yielded a B-cell
depletion of greater than 2.4 logs (range, >0.4 to >5.1 logs).
The measurement of the extent of target cell depletion is
highly dependent on the number of target cells in the pre-
depletion apheresis product as well as the limit of detection
of the assay used to quantify the target cells. Four of the
10 patients in this study had no detectable B-cells in the
predepletion product, possibly because of the use of
cyclophosphamide in the mobilization regimen. Further-
more, of these 4 patients, 1 patient had been treated with
rituximab prior to enrollment in the study, and 1 patient had
received ﬂudarabine, agents known to reduce the number of
circulating B-cells and total lymphocytes, respectively.
One of the problems of CD34 selection is the potential
loss of both progenitors and other effector cells [46]. In the
present study there was limited impact on the recovery of
nontarget cells including CD34+ and CD3+ cells. Recovery
of CD34+ cells is important because of the correlation
between the number of CD34+ cells infused and the speed
and durability of engraftment [45]. Recovery of CD3+ cells
is important because delays in lymphoid reconstitution may
predispose patients to severe opportunistic infections, such
as cytomegalovirus [18,19]. This predisposition to infection
has been reported following the use of CD34 selection prior
to ASCT in an attempt to minimize the risk of reinfusion of
potentially contaminating tumor cells.
One concern in this pilot trial was toxicity due to the infu-
sion of cells treated with a device consisting of murine mono-
clonal antibodies conjugated to nickel particles. We observed
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no signiﬁcant infusional toxicity that could be ascribed to the
use of the BCell-HDM Cell Separation System. Moreover, we
found no evidence of in vivo exposure to nickel or murine
monoclonal antibody, nor did any patient develop an HAMA
response after infusion of the treated PBSCs.
In summary, use of the BCell-HDM Cell Separation
System resulted in marked reduction of B-cells without
signiﬁcant impact on recovery of nontarget cells. Treatment
of PBSCs did not appear to alter the rate of neutrophil and
platelet recovery posttransplantation. Future studies using
this device will be focused on comparing target B-cell deple-
tion, target cell recovery, and engraftment in a randomized
trial and ultimately determining the impact on disease-free
survival of purging PBSCs prior to autologous transplanta-
tion in B-cell NHL.
ACKNOWLEDGMENTS
This work was supported by NIH grant CA 66996.
We are indebted to the nurses, adult oncology fellows,
and social workers of the Dana-Farber Cancer Institute and
the housestaff and nursing staff of the Brigham and Wom-
en’s Hospital for their excellent care of these patients. We
also thank the staff of the Dana-Farber Cancer Institute
Blood Donor Center and the Connell and O’Reilly Families
Cell Manipulation Core Facility for the care taken in the
collection and processing of the PBSC.
REFERENCES
1. Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone
marrow transplantation as compared with salvage chemotherapy
in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma.
N Engl J Med. 1995;333:1540-1545.
2. Haioun C, Lepage E, Gisselbrecht C, et al. Beneﬁt of autologous
bone marrow transplantation over sequential chemotherapy in
poor-risk aggressive non-Hodgkin’s lymphoma: updated results of
the prospective study LNH87-2. Groupe d’Etude des Lym-
phomes de l’Adulte. J Clin Oncol. 1997;15:1131-1137.
3. Haioun C, Lepage E, Gisselbrecht C, et al. Survival benefit of
high-dose therapy in poor-risk aggressive non-Hodgkin’s lym-
phoma: final analysis of the prospective LNH87-2 protocol—a
groupe d’Etude des lymphomes de l’Adulte study. J Clin Oncol.
2000;18:3025-3030.
4. Freedman AS, Ritz J, Neuberg D, et al. Autologous bone marrow
transplantation in 69 patients with a history of low grade B cell
non-Hodgkin’s lymphoma. Blood. 1991;77:2524-2529.
5. Freedman A, Gribben J, Neuberg D, et al. High dose therapy and
autologous bone marrow transplantation in patients with follicu-
lar lymphoma during ﬁrst remission. Blood. 1996;88:2780-2786.
6. Freedman A, Neuberg D, Mauch P, et al. Long-term follow-up of
autologous bone marrow transplantation in patients with relapsed
follicular lymphoma. Blood. 1999;94:3325-3333.
7. Colombat P, Donadio D, Fouillard L, et al. Value of autologous
bone marrow transplantation in follicular lymphoma: a France
Autogreffe retrospective study of 42 patients. Bone Marrow Trans-
plant. 1994;13:157-162.
8. Rohatiner A, Johnson P, Price C, et al. Myeloablative therapy
with autologous bone marrow transplantation as consolidation
therapy for recurrent follicular lymphoma. J Clin Oncol. 1994;12:
1177-1124.
9. Bierman P, Vose J, Anderson J, Bishop M, Kessinger A, Armitage J.
High-dose therapy with autologous hematopoietic rescue for fol-
licular low-grade non-Hodgkin’s lymphoma. J Clin Oncol.
1997;15:445-450.
10. Fouillard L, Laporte J, Labopin M, et al. Autologous stem-cell
transplantation for non-Hodgkin’s lymphomas: the role of graft
purging and radiotherapy posttransplantation—results of a retro-
spective analysis on 120 patients autografted in a single institu-
tion. J Clin Oncol. 1998;16:2803-2816.
11. Horning SJ, Negrin RS, Hoppe RT, et al. High-dose therapy and
autologous bone marrow transplantation for follicular lymphoma
in ﬁrst complete or partial remission: results of a phase II clinical
trial. Blood. 2001;97:404-409.
12. Brenner M, Rill D, Moen R, et al. Gene-marking to trace origin
of relapse after autologous bone-marrow transplantation. Lancet.
1993;341:85-86.
13. Deisseroth A, Zu Z, Claxton D, et al. Genetic marking shows that
Ph+ cells present in autologous transplants of chronic myeloge-
nous leukemia (CML) contribute to relapse after autologous bone
marrow in CML. Blood. 1994;83:3068-3076.
14. Gribben J, Freedman A, Neuberg D, et al. Immunologic purging of
marrow assessed by PCR before autologous bone marrow transplan-
tation for B-cell lymphoma. N Engl J Med. 1991;325:1525-1533.
15. Sharp JG, Kessinger A, Mann S, et al. Outcome of high-dose
therapy and autologous transplantation in non-Hodgkin’s lym-
phoma based on the presence of tumor in the marrow or infused
hematopoietic harvest. J Clin Oncol. 1996;14:214-219.
16. Di Nicola M, Siena S, Corradini P, et al. Elimination of bcl-2-IgH-
positive follicular lymphoma cells from blood transplants with high
recovery of hematopoietic progenitors by the miltenyi CD34+ cell
sorting system. Bone Marrow Transplant. 1996;18:1117-1121.
17. Vescio R, Schiller G, Stewart AK, et al. Multicenter phase III trial
to evaluate CD34(+) selected versus unselected autologous
peripheral blood progenitor cell transplantation in multiple
myeloma. Blood. 1999;93:1858-1868.
18. Holmberg LA, Boeckh M, Hooper H, et al. Increased incidence of
cytomegalovirus disease after autologous CD34-selected periph-
eral blood stem cell transplantation. Blood. 1999;94:4029-4035.
19. Friedman J, Lazarus HM, Koc ON. Autologous CD34+ enriched
peripheral blood progenitor cell (PBPC) transplantation is associ-
ated with higher morbidity in patients with lymphoma when com-
pared to unmanipulated PBPC transplantation. Bone Marrow
Transplant. 2000;26:831-836.
20. Bast RC Jr, De Fabritiis P, Lipton J, et al. Elimination of malignant
clonogenic cells from human bone marrow using multiple mono-
clonal antibodies and complement. Cancer Res. 1985;45:499-503.
21. Shimazaki C, Wisniewski D, Scheinberg DA, et al. Elimination of
myeloma cells from bone marrow by using monoclonal antibodies
and magnetic immunobeads. Blood. 1988;72:1248-1254.
22. Schouten HC, Kvaloy S, Sydes M, Qian W, Fayers PM. The
CUP trial: a randomized study analyzing the efﬁcacy of high dose
therapy and purging in low-grade non-Hodgkin’s lymphoma
(NHL). Ann Oncol. 2000;11:91-94.
23. Magni M, Di Nicola M, Devizzi L, et al. Successful in vivo purg-
ing of CD34-containing peripheral blood harvests in mantle cell
and indolent lymphoma: evidence for a role of both chemo-
therapy and rituximab infusion. Blood. 2000;96:864-869.
24. Voso MT, Pantel G, Weis M, et al. In vivo depletion of B cells
using a combination of high-dose cytosine arabinoside/mitox-
antrone and rituximab for autografting in patients with non-
Hodgkin’s lymphoma. Br J Haematol. 2000;109:729-735.
I. J. Webb et al.
434
25. Schmittling R, Lu T, Monroy R. Rapid and effective depletion of
B cells using CD19 and CD20 monoclonal antibodies coupled to
high density microparticles (HDM). Blood. 1998;92:492a.
26. Alyea E, Canning C, Houde H, et al. A pilot study of CD8+ cell
depletion of donor lymphocyte infusions (DLI) using CD8 mono-
clonal antibody coated high density microparticles (HDM). Blood.
1999;94:161a.
27. Houde H, Zhu H, Schmittling R, Cook D, Monroy R. A simu-
lated use of controlled study of 22 normal volunteers using the
BCell-HDM cell separation system demonstrates highly efﬁcient
depletion of CD20+ B cells and high recovery of CD34+ and
CD3+ cells. Blood. 2000;96:187a.
28. Marolleau J, Hubert V, Lacassegne M, et al. B cell purging of cry-
opreserved peripheral blood progenitor cell (PBPC) collections
using CD19-HDM and CD20-HDM with the BCell-HDM cell
separation system. Blood. 2000;96:325b.
29. National Cancer Institute sponsored study of classiﬁcation of non-
Hodgkin’s lymphomas: summary and description of a working for-
mulation for clinical usage. The Non-Hodgkin’s Lymphoma
Pathologic Classiﬁcation Project. Cancer. 1982;49:2112-2135.
30. Harris N, Jaffe E, Stein H, et al. Perspective: a revised European
American classiﬁcation of lymphoid neoplasm: a proposal from the
International Lymphoma Study Group. Blood. 1994;84:1361-1392.
31. Freedman AS, Takvorian T, Anderson KC, et al. Autologous
bone marrow transplantation in B-cell non-Hodgkin’s lymphoma:
very low treatment-related mortality in 100 patients in sensitive
relapse. J Clin Oncol. 1990;8:1-8.
32. Wheeler C, Antin JH, Churchill WH, et al. Cyclophosphamide,
carmustine, and etoposide with autologous bone marrow trans-
plantation in refractory Hodgkin’s disease and non-Hodgkin’s
lymphoma: a dose-ﬁnding study. J Clin Oncol. 1990;8:648-656.
33. Ross AA, Cooper BW, Lazarus HM, et al. Detection and viability
of tumor cells in peripheral blood stem cell collections from
breast cancer patients using immunocytochemical and clonogenic
assay techniques. Blood. 1993;82:2605-2610.
34. Sutherland DR, Anderson L, Keeney M, Nayar R, Chin-Yee I.
The ISHAGE guidelines for CD34+ cell determination by ﬂow
cytometry. International Society of Hematotherapy and Graft
Engineering. J Hematother. 1996;5:213-226.
35. Armitage JO, Weisenburger DD. New approach to classifying
non-Hodgkin’s lymphomas: clinical features of the major histo-
logic subtypes. Non-Hodgkin’s Lymphoma Classiﬁcation Project.
J Clin Oncol. 1998;16:2780-2795.
36. Gribben J, Freedman A, Woo S, et al. All advanced stage non-
Hodgkin’s lymphomas with a polymerase chain reaction ampliﬁ-
able breakpoint of bcl-2 have residual cells containing the bcl-2
rearrangement at evaluation and after treatment. Blood. 1991;78:
3275-3280.
37. Berinstein NL, Jamal HH, Kuzniar B, Klock RJ, Reis MD. Sensi-
tive and reproducible detection of occult disease in patients with
follicular lymphoma by PCR ampliﬁcation of t(14; 18) both pre-
and post-treatment. Leukemia. 1993;7:113-119.
38. Hickish TF, Purvies H, Mansi J, Soukop M, Cunningham D.
Molecular monitoring of low grade non-Hodgkin’s lymphoma by
gene ampliﬁcation. Br J Cancer. 1991;64:1161-1163.
39. Lambrechts AC, Hupkes PE, Dorssers LCJ, van’t Veer MB. Clini-
cal signiﬁcance of translocation t(14;18) positive cells in the circu-
lation of patients with stage III or IV follicular non-Hodgkin’s
lymphoma during ﬁrst remission. J Clin Oncol. 1994;12:1541-1546.
40. Bastion Y, Brice P, Haioun C, et al. Intensive therapy with
peripheral blood progenitor cell transplantation in 60 patients
with poor-prognosis follicular lymphoma. Blood. 1995;86:
3257-3262.
41. Haas R, Moos M, Karcher A, et al. Sequential high dose therapy
with peripheral blood progenitor cell support in low grade non-
Hodgkin’s lymphoma. J Clin Oncol. 1994;12:1685-1692.
42. Gorin NC, Lopez M, Laporte JP, et al. Preparation and success-
ful engraftment of purified CD34+ bone marrow progenitor
cells in patients with non-Hodgkin’s lymphoma. Blood. 1995;85:
1647-1654.
43. Williams C, Goldstone A, Pearce R, et al. Purging of bone mar-
row in autologous bone marrow transplantation for non-Hodgk-
in’s lymphoma: a case matched comparison with unpurged cases
by the European Blood and Marrow Transplant Lymphoma Reg-
istry. J Clin Oncol. 1996;14:2454-2464.
44. Leonard BM, Hetu F, Busque L, et al. Lymphoma cell burden in
progenitor cell grafts measured by competitive polymerase chain
reaction: less than one log difference between bone marrow and
peripheral blood sources. Blood. 1998;91:331-339.
45. Shpall E, Champlin R, Glaspy J. Effect of CD34+ peripheral
blood progenitor cell dose on hematopoietic recovery. Biol Blood
Marrow Transplant. 1998;4:84-92.
46. Johnsen HE, Hutchings M, Taaning E, et al. Selective loss of
progenitor subsets following clinical CD34+ cell enrichment by
magnetic field, magnetic beads or chromatography separation.
Bone Marrow Transplant. 1999;24:1329-1336.
